Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
This week on “The Readout LOUD”: We discuss financial outlooks from Novo Nordisk and Eli Lilly, a closer look at why manufacturing problems have slowed the rollout of a crucial…
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal…
Novo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis
CONCLUSIONS: GLP-1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.
Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis
Excess body weight and poor metabolic control remain major contributors to cardiometabolic disease, highlighting the need for effective therapeutic options. This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes. Searches were conducted across four databases through November 2025. Five randomized controlled trials (n = 6140) were included. Orforglipron produced consistent, dose-dependent reductions in body weight,…
A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
CONCLUSIONS: TEAEs and treatment discontinuations due to macronutrient malnutrition were uncommon in the SURMOUNT-1-4 trials of tirzepatide for obesity. Lack of routinely collected vitamin and mineral levels during the trials limited assessment of the impact of tirzepatide treatment on micronutrient status. Systematic assessment of nutritional status before and during OMM treatment would enhance future trials.
Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity
Childhood obesity is a global health crisis with limited effective therapies beyond lifestyle modification. This review examines the growing role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the management of pediatric obesity. Simultaneously, this study highlights the critical considerations for clinicians in administering these medications, including long-term safety, efficacy, potential adverse effects, and overall clinical utility. To enhance the effectiveness of GLP-1 RAs in…
Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women
CONCLUSION: Clinicians should consider recommending individualized exercise programs and dietary strategies for older patients taking GLP-1 RAs. Routine assessment of body composition may help guide interventions and optimize clinical outcomes.
GLP-1s and the Super Bowl
The Super Bowl is once again getting the GLP-1 ad treatment.
Hims & Hers is back with another combative spot that calls out the disparities in healthcare experiences between the …